| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6423cd23d4f0f465a873a1adb376991
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66aeee44b2587b3b10ab88227b415f56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c77135d4de6b03f9556c4dae7cfbb88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38cd905c010b5d6a52bc7a4a93b7f20a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1a941a52ae51a06b1b89197acb63c22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_efff944a679d83f88436b99bdc0f2baa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06F19-20 |
| filingDate |
2011-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e16ac19432b42481d774405638e3bd4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1ad3204300e4ea1296a4af8262b024c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a46079cae633bb69d40846e8b843b48f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31d1a41170016ee9bd198bca64d6776d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_597792901057fd1a075afd7077d6beb6 |
| publicationDate |
2012-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012072124-A1 |
| titleOfInvention |
Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| abstract |
The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113265465-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013169771-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013169771-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022221462-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10318503-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9607023-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114621962-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10253371-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101865198-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170115894-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10745759-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9336302-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11205103-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11216428-B1 |
| priorityDate |
2005-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |